Multiple Myeloma

The AJMC^® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

These studies highlight that multiple myeloma outcomes are not solely determined by disease biology or available therapies. | Image Credit: wladimir1804 - stock.adobe.com

Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

By Kimberly Rath, PharmD

June 28th 2025

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.

Westin Forrestal Princeton | Image: Westin

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

By Mary Caffrey

June 19th 2025

Mansi Shah, MD

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

By Laura Joszt, MA
Hayden E. Klein

June 11th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

By Jared Kaltwasser

June 7th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

By Laura Joszt, MA

May 19th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

Continuing Medical Education

June 30th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 30th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

June 30th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

June 30th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Expert on MM

January 14th 2022

The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma

Rafael Fonseca, MD

Expert perspective on results from the MASTER trial, which analyzed dara-KRd as frontline therapy with MRD-adapted use in newly diagnosed multiple myeloma.

Robert Rifkin, MD, FACP

January 13th 2022

Dr Robert Rifkin on Future Investigations Into Multiple Myeloma

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines multiple myeloma research he hopes to see in the next 5 years.

data set

January 11th 2022

Interview: Real-World Data Show Daratumumab 1L Improves OS in Some Patients With MM

For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?

Robert Rifkin, MD, FACP

January 7th 2022

Dr Robert Rifkin Describes Research on Triple-Class Refractory MM Patients

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses his research using real-world data from patients with triple-class refractory multiple myeloma.

old man

January 3rd 2022

Analysis Identifies Potential Biomarker of Frailty in Multiple Myeloma

Neutrophil to lymphocyte ratio may indicate the presence of frailty among older adults with multiple myeloma.

Robert Rifkin, MD, FACP

December 31st 2021

Dr Robert Rifkin Discusses Treatment Resistance in Multiple Myeloma

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines the importance of studying treatment resistant patients with multiple myeloma.

Expert on Multiple Myeloma

December 23rd 2021

Upcoming Post-Conference Perspectives: ASH 2021

Rafael Fonseca, MD

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

scientists in lab

December 22nd 2021

Phase 1/2 Trial Results Underscore Teclistamab’s Efficacy in RRMM

Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Robert Rifkin, MD, FACP

December 20th 2021

Dr Robert Rifkin Explains the Importance of Real-world Data in MM Patient Populations

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

December 18th 2021

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

Five years ago, investigators in Iceland sought to evaluate what would happen if screening for MGUS were widely available—and whether it would improve overall survival.

Picture of abnormal cells in bone marrow

December 15th 2021

Sub-Q Isatuximab Combo Offers Safety, Efficacy Profile Comparable With Phase 3 Results in IV Formulation

Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.

December 8th 2021

The MMRF: Understanding and Sharing the Genomic Landscape of Multiple Myeloma

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

December 8th 2021

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

blue cross

December 6th 2021

Postmarketing Surveillance Study Finds Ixazomib Safety Profile Acceptable in RRMM

Real-world evidence from Japan found ixazomib has an acceptable safety profile in patients with relapsed/refractory multiple myeloma (RRMS).

pills in box

December 1st 2021

Real-world Evidence Details Use of Ixazomib as Maintenance Therapy for MM

Results of a retrospective study conducted in China assessed the safety and efficacy of ixazomib for multiple myeloma.

elderly woman

April 4th 2021

Older Patients With MM Can Forgo Steroids in Treatment and See Similar Outcomes

Laura Joszt, MA

The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.

red blood cells

March 25th 2021

Trial Analyzes Efficacy of Tailoring MM Treatment to MRD Response

Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.

Optimizing the Use of MRD Testing in Multiple Myeloma

March 18th 2021

Optimizing the Use of MRD Testing in Multiple Myeloma

Laura Joszt, MA

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Highlighting Resiliency During Multiple Myeloma Awareness Month 2021

March 13th 2021

Highlighting Resiliency During Multiple Myeloma Awareness Month 2021

Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition.

CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma

March 10th 2021

CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma

Laura Joszt, MA

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.

...

7 8 9 10 11 12 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions